# QuidelOrtho Corp: overview

QDEL · Nasdaq · CIK 1906324 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jan 1

Pages: [Overview](/companies/qdel.md) · [Financials](/companies/qdel/financials.md) · [Filings](/companies/qdel/filings.md) · [Insiders](/companies/qdel/insiders.md)

Latest reported revenue: [$630.9m](/filings/0001906324-26-000033.md) for Q2 FY2026, three months to 2026-06-28, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:Revenues, accession 0001906324-26-000033).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-29) | Q4 FY2024 (2024-12-29) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | Q4 FY2025 (2025-12-28) | Q1 FY2026 (2026-03-29) | Q2 FY2026 (2026-06-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [727](/filings/0001906324-25-000160.md) | [708 d](/filings/0001906324-26-000008.md) | [693](/filings/0001906324-26-000024.md) | [614](/filings/0001906324-26-000033.md) | [700](/filings/0001906324-25-000160.md) | [724 d](/filings/0001906324-26-000008.md) | [620](/filings/0001906324-26-000024.md) | [631](/filings/0001906324-26-000033.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [2.1%](/filings/0001906324-25-000160.md) | [(14.2%) d](/filings/0001906324-26-000008.md) | [4.7%](/filings/0001906324-26-000024.md) | [(29.4%)](/filings/0001906324-26-000033.md) | [(100.7%)](/filings/0001906324-25-000160.md) | [(9.2%) d](/filings/0001906324-26-000008.md) | [(5.1%)](/filings/0001906324-26-000024.md) | [(3.5%)](/filings/0001906324-26-000033.md) |
| Net margin | % | [(2.7%)](/filings/0001906324-25-000160.md) | [(25.2%) d](/filings/0001906324-26-000008.md) | [(1.8%)](/filings/0001906324-26-000033.md) | [(41.6%)](/filings/0001906324-26-000033.md) | [(104.7%)](/filings/0001906324-25-000160.md) | [(18.1%) d](/filings/0001906324-26-000008.md) | [(14.8%)](/filings/0001906324-26-000033.md) | [(14.7%)](/filings/0001906324-26-000033.md) |
| Diluted EPS | $ per share | [(0.30)](/filings/0001906324-25-000160.md) | not reported | [(0.19)](/filings/0001906324-26-000024.md) | [(3.77)](/filings/0001906324-26-000033.md) | [(10.78)](/filings/0001906324-25-000160.md) | not reported | [(1.35)](/filings/0001906324-26-000024.md) | [(1.36)](/filings/0001906324-26-000033.md) |
| Free cash flow | $m | [71.4 d](/filings/0001906324-25-000160.md) | [16.5 d](/filings/0001906324-26-000008.md) | [9.4](/filings/0001906324-26-000024.md) | [(84.3) d](/filings/0001906324-26-000033.md) | [(94.7) d](/filings/0001906324-25-000160.md) | [86.6 d](/filings/0001906324-26-000008.md) | [(67.0)](/filings/0001906324-26-000024.md) | [(136) d](/filings/0001906324-26-000033.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2022-01-02) | FY2022 (2023-01-01) | FY2023 (2023-12-31) | FY2024 (2024-12-29) | FY2025 (2025-12-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,699](/filings/0001906324-24-000043.md) | [3,266](/filings/0001906324-25-000035.md) | [2,998](/filings/0001906324-26-000008.md) | [2,783](/filings/0001906324-26-000008.md) | [2,730](/filings/0001906324-26-000008.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [53.3%](/filings/0001906324-24-000043.md) | [25.8%](/filings/0001906324-25-000035.md) | [4.6%](/filings/0001906324-26-000008.md) | [(70.5%)](/filings/0001906324-26-000008.md) | [(33.7%)](/filings/0001906324-26-000008.md) |
| Net margin | % | [41.5%](/filings/0001906324-24-000043.md) | [16.8%](/filings/0001906324-25-000035.md) | [(0.3%)](/filings/0001906324-26-000008.md) | [(73.7%)](/filings/0001906324-26-000008.md) | [(41.5%)](/filings/0001906324-26-000008.md) |
| Diluted EPS | $ per share | [16.43](/filings/0001906324-24-000043.md) | [9.56](/filings/0001906324-25-000035.md) | [(0.15)](/filings/0001906324-26-000008.md) | [(30.54)](/filings/0001906324-26-000008.md) | [(16.69)](/filings/0001906324-26-000008.md) |
| Free cash flow | $m | [513](/filings/0001906324-24-000043.md) | [744](/filings/0001906324-25-000035.md) | [70.9](/filings/0001906324-26-000008.md) | [(112)](/filings/0001906324-26-000008.md) | [(83.0)](/filings/0001906324-26-000008.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/qdel/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $196.2m | 11,202,523 |  | Added +753,396 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $129.0m | 7,363,696 |  | Added +772,544 |
| [Newtyn Management, LLC](/funds/1569241.md) | 2026-06-30 | $116.0m | 6,625,000 |  | Added +2,066,528 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $72.4m | 4,135,464 |  | Added +103,696 |
| [NEUBERGER BERMAN GROUP LLC](/funds/1465109.md) | 2026-06-30 | $62.1m | 3,534,619 |  | Added +2,004,205 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $60.8m | 3,473,432 |  | Added +355,963 |
| [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $57.9m | 3,307,079 |  | Added +450,947 |
| [Rubric Capital Management LP](/funds/1687509.md) | 2026-06-30 | $57.9m | 3,306,281 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $53.8m | 3,070,054 |  | Added +17,344 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $52.2m | 2,978,639 |  | Added +192,018 |

## Recent filings

[All 461 filings](/companies/qdel/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-23 | 20:41 ET | [8-K](/filings/0001906324-26-000036.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001906324-26-000036 |
| 2026-08-07 | 21:46 ET | [10-Q](/filings/0001906324-26-000033.md) | Quarterly report, period 2026-06-28 | 0001906324-26-000033 |
| 2026-08-06 | 20:08 ET | [8-K](/filings/0001906324-26-000032.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001906324-26-000032 |
| 2026-06-23 | 20:04 ET | [8-K](/filings/0001906324-26-000028.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001906324-26-000028 |
| 2026-06-16 | 20:31 ET | [8-K](/filings/0001193125-26-272707.md) | 5.07 Shareholder vote results | 0001193125-26-272707 |
| 2026-05-06 | 21:46 ET | [10-Q](/filings/0001906324-26-000024.md) | Quarterly report, period 2026-03-29 | 0001906324-26-000024 |
| 2026-05-05 | 20:07 ET | [8-K](/filings/0001906324-26-000023.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001906324-26-000023 |
| 2026-04-27 | 20:05 ET | [DEF 14A](/filings/0001906324-26-000018.md) | Proxy statement, period 2026-06-16 | 0001906324-26-000018 |
| 2026-04-15 | 20:15 ET | [8-K](/filings/0001906324-26-000013.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001906324-26-000013 |
| 2026-03-24 | 11:00 ET | [8-K](/filings/0001193125-26-120684.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-120684 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 28, 2025](/filings/0001906324-26-000008.md), filed Feb 19, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-28, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/733f0ca4-9130-4b53-b0ec-d01c35a83061)

## About the filer

- CIK: 1906324
- Tickers: QDEL
- Exchange: Nasdaq
- SIC code: 2835 In Vitro & In Vivo Diagnostic Substances
- State of incorporation: not reported
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.